about
Therapeutic antibodies, vaccines and antibodyomesImmune Modulation in Hematologic MalignanciesTumor antigen-specific monoclonal antibodies and induction of T-cell immunityAnti-idiotypic antibodies as cancer vaccines: achievements and future improvementsCombination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitorsAlphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunityElotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Mining human antibody repertoires.Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells.Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responsesChemoimmunotherapy.Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model.Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78.Polyclonal rabbit anti-murine plasmacytoma cell globulins induce myeloma cells apoptosis and inhibit tumour growth in mice.Structural basis for the recognition in an idiotype-anti-idiotype antibody complex related to celiac disease.Development trends for generation of single-chain antibody fragments.Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12Therapeutic vaccines for gastrointestinal cancers.Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascitesHidden immunotherapy targets challenge dogmaImmunotherapy of cancer in 2012.CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment.IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.Toll-like receptor 2 ligands regulate monocyte Fcγ receptor expression and function.Research and development of therapeutic mAbs: An analysis based on pipeline projects.EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical EffectsIntratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors.Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.From rabbit antibody repertoires to rabbit monoclonal antibodiesVaccine-induced antibody responses in patients with carcinoma.Unravelling the complexity of cancer-immune system interplay.
P2860
Q24599662-9FA59636-74BA-4D89-BAD6-9FEB4DC75829Q26796307-EC12DB7F-76DE-490C-A26D-FA0FFBBC4ADEQ27009908-733C05F2-5796-4A5D-8B34-AF22A175F118Q28278814-5664353A-9261-4003-9511-241950440E23Q28537997-4FFB6EC6-728E-4313-8F6B-3BAC01B3655AQ28749317-17CD9DB4-E401-4D3E-90AA-E2A315023A49Q30249513-A94DAE1C-88A0-4D79-8AE0-B11D08CB980AQ33588489-D4BFCC3E-C4B0-4ED7-8C39-07F5B07AEA2AQ33620053-A5AD702B-E0D6-4F3E-B395-ECB4DAD9F8FCQ33620107-5559060D-B19D-454D-B993-559549DAF6EBQ34058792-94D21682-CDEE-4C17-8CA6-19E67E93896CQ34194706-0E2D9CCB-54B8-40C3-8A8B-D9A91E44AB24Q34331673-E5717C71-AAD1-445E-A15A-406BB97DBC32Q34404779-42B98F5A-017C-4B5C-81FF-C757A3BC1A16Q34718149-29310C5C-D5CF-43F9-9711-E8435641267AQ34733945-185B992C-9CB9-49AF-935C-8F95D583CA0CQ35215675-B4C3FFA2-8AED-45B0-9632-CACF14CFDF62Q35216785-367CED7D-6F3A-492D-B760-A1AE7CDDF84DQ35437978-650FC266-54DF-44F6-800A-149B226243EDQ35564007-59991D9E-003E-4A5D-9C59-79E41CFD133BQ35624686-4542BBA5-7C3D-42AD-9ECD-F4152A492BF7Q35691248-410DF0C4-981A-4A87-A4F4-715D786566CCQ35963440-0244B8C4-4CA2-4415-BA18-F6AEE3166E85Q36153347-17C7834E-57BB-40D7-A38E-FB020C70DEE1Q36184951-3297B252-20CA-407E-9BF7-8F8D722AFEA8Q36243536-B5FCCE58-1DE7-44ED-BF67-E4C6044D28FBQ36288270-A5A0B8B4-BC56-48D1-8F30-09AE90298F0FQ36455017-54027983-343C-4C6D-9DAE-5429774486F9Q36671364-5E5D432E-425D-462E-B40F-DFAA63F50A1CQ36796964-D2872642-6F29-4DCF-ACEC-E42C307DAEC9Q37027607-C3382EBB-EAAC-43A2-95A4-BEAFDF50F988Q37132708-3FC417CC-0E4C-44E3-89BF-A278393E6FE8Q37322304-2D431E55-CF05-48FB-8E69-15D1354C75B7Q37468539-1D47A05B-A9D8-4465-B67C-7DAF2D89B742Q37593675-CD063E80-6D04-4272-A1BC-7153D2D794DEQ37650735-92F1EE91-B634-4A3B-AE44-235590B08A4AQ37686302-BF84AD65-81B2-4570-BD92-EB19B39F81DCQ37739483-1E680863-B9FA-4414-92A4-F411EA88293AQ37762272-BE0CA7E5-D5E6-44F4-BCF4-53F022B7BC78Q37765590-4221D183-E392-424B-832D-FB66C81A1E07
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Monoclonal antibodies for cancer immunotherapy.
@en
Monoclonal antibodies for cancer immunotherapy.
@nl
type
label
Monoclonal antibodies for cancer immunotherapy.
@en
Monoclonal antibodies for cancer immunotherapy.
@nl
prefLabel
Monoclonal antibodies for cancer immunotherapy.
@en
Monoclonal antibodies for cancer immunotherapy.
@nl
P2093
P2860
P1433
P1476
Monoclonal antibodies for cancer immunotherapy.
@en
P2093
Louis M Weiner
Madhav V Dhodapkar
Soldano Ferrone
P2860
P304
P356
10.1016/S0140-6736(09)60251-8
P407
P577
2009-03-01T00:00:00Z